ABOUT WUXI BIOLOGICS
WuXi Biologics is a global contract research, development, and manufacturing organization (CRDMO). Through a fully integrated, end-to-end service model, we seamlessly connect discovery, development, and manufacturing, eliminating vendor hand-offs and reducing complexity across the drug development lifecycle. This streamlined approach, supported by a deep bench of over 12,000 employees, accelerates timelines while maintaining uncompromising quality. A comprehensive suite of standalone CMC services maximizes flexibility, filling gaps and adapting as programs evolve.
We manage a continuously growing global network spanning 6 countries, operating under a unified quality system that ensures consistency and compliance worldwide. With a proven regulatory track record featuring over 1,800 client quality audits, including more than 230 Qualified Person audits, WuXi Biologics brings confidence to every milestone.
Advanced mammalian and microbial expression systems support a wide range of modalities, from monoclonal antibodies to complex biologics such as bispecific antibodies and antibody-drug conjugates. WuXia™ TrueSite, WuXiHigh™ 2.0, and other technology platforms further strengthen our capabilities, enhancing productivity, efficiency, and product quality.
Key performance highlights include an industry-leading 6-month DNA-to-IND timeline and total bioreactor capacity exceeding 500,000 L for easy scalability. In-house media reduces medium costs by up to 40%, with overall cost reductions reaching as high as 30%. As a leading CRDMO, we combine scientific expertise, global capacity, and innovative technologies to help partners accelerate biologics development for patients worldwide.
INDUSTRY INSIGHTS
-
![mammlian-cell-lines-GettyImages-1690936576]( "Mammalian Cell Line Development")
Explores how modern cell line engineering boosts speed, stability, and scalability across biologics, with practical insights to cut risk and improve readiness for downstream development.
-
![biologic-tech-transfer-GettyImages-2157720330]( "Rapid, Reliable Technology Transfer")
See how structured planning, expert coordination, and risk‑focused execution speed tech transfer, improve consistency, and move biologics into manufacturing faster.
-
![biologic-medicine-research-GettyImages-1413606459]( "WuXiHigh 2.0 Delivers A 180 mg/mL Formula")
This case study shows how smart formulation and integrated development achieved a stable 180 mg/mL biologic for subcutaneous delivery, for teams tackling concentration issues.
-
![bio-manufacturing-GettyImages-2194012901]( "Systematic Strategy To Reduce The Cost Of Goods Sold")
Learn key ways to cut biologics manufacturing costs through smarter process design, material choices, and supply resilience — driving more efficient, reliable, and commercially sustainable production.
-
![WuXia293Stable]( "WuXia293Stable: Express What CHO Can't")
Discover a modern 293‑based expression system built for higher purity, controlled glycosylation, and improved activity, offering a new option for teams developing complex or next‑generation biologics.
-
![biologics-GettyImages-2149749974]( "WuXiHigh 2.0 In Action")
Explore the growing demand for high‑concentration biologics, and the formulation, viscosity, and manufacturing challenges driving new technologies for stable, scalable drug development.
-
![enzymes-drug-conjugte-GettyImages-1343098807]( "Tool Enzymes For Antibody-Drug Conjugate Development And Manufacturing")
See how modern tool enzymes enable cleaner, more consistent ADC conjugation, sharper analytics, and a smoother path from research to clinical development — practical guidance for manufacturing.
-
![Global Manufacturing Excellenence]( "Global Manufacturing Excellence Across Quality, Efficiency, And Cost Of Goods Sold")
Learn strategies to strengthen global biologics manufacturing through consistent quality, advanced technologies, and efficient tech transfer to improve operations and commercial readiness.
-
![Ensure Successful Viral Clearance]( "Ensure Successful Viral Clearance")
A decade of viral clearance data comparing established and emerging operations, highlighting LRV performance, key process risks, and practical insights to strengthen downstream safety.
-
![Deciphering the Complexity Of Therapeutic Biologics]( "Deciphering The Complexity Of Therapeutic Biologics")
This session breaks down essential analytical approaches that strengthen biologics development, from defining critical quality attributes to supporting comparability and regulatory readiness.
CONTACT INFORMATION
WuXi Biologics
108 Meiliang Road, Mashan, Binhu District, Wuxi
Jiangsu, 214092
CHINA
SOLUTIONS
-
![research-drugdevelopment-GettyImages-2254140660]( "Selected Drug Product Publications")
Recent studies offer insights on formulation, device compatibility, stability testing, and fill‑finish optimization — helping teams boost product performance and cut development risk.
-
![cmo-biologics-GettyImages-1327624070]( "WuXi Biologics Services Overview")
Learn how integrated R&D and manufacturing streamline the journey from discovery to large-scale production, helping teams advance biologics faster and with greater confidence.
-
![dna-to-indGettyImages-2149039471]( "DNA To IND Service")
See how coordinated development — from DNA construct through IND submission —helps teams streamline decision‑making, strengthen data continuity, and prepare more confidently for early clinical milestones.
